Hunter Syndrome Treatment Market

Report Description
Table of Contents

Report Description

The global hunter syndrome treatment market size is estimated to be USD 995.71 million in 2021 and is expected to witness a CAGR of 7.83% during the forecast period. Increase in number of patients suffering from hunter syndrome is a key driver for the growth of the global hunter syndrome treatment market. Additionally, the rise in initiatives taken up by the governments, introduction of novel therapies in the market, and occurrence of strong pipeline portfolio are some of the other drivers propelling the market growth. Nevertheless, the increasing cost of treatment and lack of awareness about hunter syndrome treatment are expected to restrain the global market growth.

Global Hunter Syndrome Treatment Market Size (USD Million), 2021-2029

Source: Erevna Healthcare

By Treatment

Based on treatment, the market is divided into enzyme replacement therapy (ERT), hematopoietic stem cell transplant (HSCT), and others. In 2021, the enzyme replacement therapy (ERT) segment accounted for the substantial revenue share with lucrative CAGR during the forecast period. This is due to the growing awareness, increasing availability of enzyme replacement therapy, and less severe guidelines worldwide. The hematopoietic stem cell transplant (HSCT) segment is anticipated to grow at a profitable CAGR during the forecast period, due to the increasing acceptance of these therapies by the target patient pool and increasing product approval that triggers the growth for this segment.

Regional Insights

In 2021, North America accounted for the highest revenue share in the global market and is expected to maintain its dominance during the forecast period. This is attributed to the orphan drug growth, growing attentiveness among patients regarding rare diseases, increase in investment for research activities, and better-quality healthcare facilities in the region. Asia Pacific market is projected to exhibit the fastest CAGR over the forecast period owing to the less stringent regulations, the high incidences of unmet needs, sanction for novel therapies, and availability of skilled labour forces at economic costs are the major factors in this region.

Competitor Insights

Some of the key players in the hunter syndrome treatment market are Takeda Pharmaceutical Company (Japan); GC Pharma (South Korea); JCR Pharmaceuticals Co Ltd. (Japan); RegenxBio Inc. (U.S.); Sangamo Therapeutics, Inc. (U.S.); ArmaGen Inc. (U.S.); Inventiva S.A. (France); Denali Therapeutics Inc. (U.S.); Bioasis Technologies Inc. (Canada); and Avrobio, Inc. (U.S.). The leading players operating in the Hunter syndrome treatment industry are adopting various strategies including R&D investments, the adoption of advanced techniques, new technology launches, mergers & acquisitions, and regional expansions to capture a maximum revenue share.

This exhaustive research report focuses on market size and forecast at global, segmental, regional and country level along with key market trends and dynamics from 2021 to 2029. The hunter syndrome treatment market report is categorized into the following segments and subsegments: